| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sarepta Therapeutics, Inc.$16.7
-0.57 (-3.27%)
C 46Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.77 B
EPS
-0.57
P/E Ratio
-
Value Trade
57.62 M
SEC Financials
Q1 2026Dilution Risk
Revenue
730.80 M
R&D Expenses
153.96 M
Operating CF
-202.68 M
Total Assets
3.18 B
Total Liabilities
1.67 B
Equity
1.51 B
D/E Ratio
12,345
-8.84 %
Week
-20.23 %
1 Month
-8.65 %
3 Month
2.44 %
6 Month
-78.94 %
5 Year
-60.7 %
All Time
Cash Data
Cash Position
653.19 M
Monthly Burn
67.56 M
Runway
8.3 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
2.75 M
52 Week Range
10.42 - 43.92
% held by Insiders
4.79 %
% held by Institutions
101.15 %
Enterprise Value
2.16 B
Total Shares
104.79 M
Short %
26.01 %
Float Shares
96.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C46
Pipeline Score $545M
Pipeline ValueFair Value
Valuation Signal16
Drugs Scored1.0x
rNPV / MCap Top 70%
Micro Cap (rank 272 of 905)
Percentile RankSarepta Therapeutics, Inc. carries a moderate pipeline score (46/100), with $1.8B risk-adjusted pipeline value, led by Eteplirsen in Muscular Dystrophy, Duchenne (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eteplirsen Small molecule | Muscular Dystrophy, Duchenne | Phase 3 | NCT03992430 | 44% | $696M | ACTIVE NOT_RECRUITING | 184 | SLOW | B (70) | Oct 31, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ELEVIDYS (delandistrogene moxeparvovec) | Duchenne muscular dystrophy | Phase 1 | 2025-07-21 | |||
ELEVIDYS (delandistrogene moxeparvovec) | Duchenne muscular dystrophy | Phase 1 | 2025-07-21 | |||
ELEVIDYS (delandistrogene moxeparvovec) | Duchenne muscular dystrophy | Phase 1 | 2025-07-21 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SRPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SRPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRPT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SRPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SRPTSarepta Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Sarepta Therapeutics, Inc. has announced its participation in investor conferences scheduled for June 2026. Senior management will present at the Goldman Sachs conference, which will be available via live webcast on the company's investor relations website. The presentation will also be archived for 90 days for future viewing.
Read more →SRPTSarepta Therapeutics to Participate in Upcoming Investor Conferences
Sarepta Therapeutics is set to participate in upcoming investor conferences. Details regarding the specific events or topics of discussion were not provided in the article. This participation may provide insights into the company's future plans and developments.
Read more →SRPTSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics is scheduled to present at the RBC Capital Markets Global Healthcare Conference. The details regarding the presentation or any specific announcements were not provided in the article.
Read more →SRPTSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics has announced its financial results for the first quarter of 2026 along with recent corporate developments. The details of the financial performance and any significant updates regarding their operations or pipeline were not disclosed in the provided text. Further insights into the company's strategic direction may be expected in future communications.
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. will announce its first quarter 2026 financial results on May 6, 2026, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss these results. The event will be available via live webcast and archived for one year on the company's investor relations website.
Read more →SRPTWhen Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
The biotechnology sector is transforming, with scientific advancements increasingly recognized as measurable financial assets. Fair-value accounting under U.S. GAAP allows companies to reflect clinical progress and commercialization timing in their financial statements. This shift is attracting institutional investors to clinical-stage biotech assets, emphasizing the importance of pipeline maturity in valuation.
Read more →SRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2026
Sarepta Therapeutics announced the granting of equity awards to 24 new employees as part of its 2024 Employment Commencement Incentive Plan. The awards, totaling 113,855 restricted stock units (RSUs), were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, contingent on continued employment.
Read more →SRPTSarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta Therapeutics will host a webcast on March 25, 2026, to share early clinical data from its Phase 1/2 studies of SRP-1001 and SRP-1003. These studies target facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1). The event will be accessible via their investor relations website.
Read more →SRPTSarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta Therapeutics announced promising early clinical data from its siRNA programs targeting FSHD1 and DM1. The Phase 1/2 studies of SRP-1001 and SRP-1003 demonstrated dose-dependent muscle exposure and favorable tolerability. Both treatments effectively reduced target protein levels, suggesting a significant advancement in RNA-targeted therapies for these rare diseases.
Read more →SRPTSarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Therapeutics has initiated screening and enrollment for Cohort 8 of the ENDEAVOR study, which evaluates an enhanced immunosuppression regimen during treatment with ELEVIDYS for non-ambulant Duchenne muscular dystrophy patients. This cohort aims to assess the safety and efficacy of sirolimus in reducing acute liver injury associated with gene therapy. The study will enroll approximately 25 participants in the U.S.
Read more →SRPTSarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics has launched the 9th Annual Route 79, The Duchenne Scholarship Program, offering up to $5,000 in academic scholarships for individuals living with Duchenne muscular dystrophy and their siblings. Applications are open until May 15, 2026, with awards distributed for the 2026-2027 academic year. The program aims to support educational pursuits and recognizes the unique perspectives of those affected by Duchenne.
Read more →SRPTSarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Sarepta Therapeutics will present new data on gene therapy and exon-skipping programs at the MDA Clinical & Scientific Conference in March 2026. The presentations will include findings from the Phase 3 EMBARK study and caregiver-reported outcomes, highlighting the long-term safety and efficacy of their treatments for Duchenne muscular dystrophy. This event aims to provide clinicians and families with critical information for treatment decisions.
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics reported its financial results for Q4 and full-year 2025, highlighting a strong cash position and revenue growth despite a decrease in Q4 revenues. The company emphasized the potential of its ELEVIDYS gene therapy and ongoing siRNA pipeline. However, it faced challenges including increased costs and restructuring charges. Looking ahead, Sarepta expects to remain profitable in 2026.
Read more →SRPTSarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Sarepta Therapeutics has announced the commercial launch of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, in Japan. The therapy is now available for children aged 3 to under 8 years who meet specific genetic criteria. The launch follows its reimbursement listing on Japan's National Health Insurance price list, and Sarepta stands to receive a $40 million milestone payment upon the first sale.
Read more →SRPTSarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Sarepta Therapeutics will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. Senior management will discuss the company's advancements in precision genetic medicine for rare diseases. The presentation will be available via live webcast and archived for 90 days on their investor relations website.
Read more →SRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Sarepta Therapeutics will announce its fourth quarter and full-year 2025 financial results on February 25, 2026. Following the announcement, a conference call will be held at 4:30 p.m. E.T. to discuss the results. The event will be accessible via webcast and phone registration is required for participants.
Read more →SRPTSarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Sarepta Therapeutics has received approval from Medsafe for its clinical trial application for SRP-1005, an investigational treatment for Huntington's Disease. The first-in-human study, named INSIGHTT, is set to begin in the second quarter of 2026 and will assess the safety and tolerability of the treatment. SRP-1005 utilizes a novel delivery method aimed at effective brain penetration.
Read more →SRPTSarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
Sarepta Therapeutics announced positive three-year results from the EMBARK study, demonstrating that ELEVIDYS significantly slows disease progression in ambulatory Duchenne muscular dystrophy patients. The study showed durable efficacy across key motor function measures, with treated patients maintaining higher motor function levels compared to an external control group. No new safety concerns were identified, supporting the therapy's manageable safety profile.
Read more →SRPTSarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Sarepta Therapeutics will present 3-year topline data from the EMBARK study on January 26, 2026. This Phase 3 study evaluates the efficacy of ELEVIDYS gene therapy in young patients with Duchenne muscular dystrophy. The event will be accessible via a live webcast and will include a replay for later viewing.
Read more →SRPTSarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Sarepta Therapeutics reported preliminary fourth quarter and full-year 2025 net product revenues, achieving $1.86 billion in total revenue. The company highlighted strong performance from its ELEVIDYS therapy, which generated $898.7 million despite challenges from a severe flu season. Sarepta ended the year with $953.8 million in cash, positioning itself well for future initiatives.
Read more →SRPTSarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will include a Q&A session and will be available via live webcast. Sarepta aims to advance precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy.
Read more →SRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 31, 2025
Sarepta Therapeutics announced the granting of equity awards to 10 new employees as part of its 2024 Employment Commencement Incentive Plan. This initiative, approved by the Compensation Committee, aligns with Nasdaq Listing Rule 5635(c)(4). The awards consist of 55,118 restricted stock units, which will vest over four years, contingent on continued employment.
Read more →SRPTSarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Sarepta Therapeutics has announced a refinancing initiative involving approximately $291 million of its existing convertible senior notes due 2027. The company will exchange these notes for new convertible senior notes with a lower interest rate due in 2030, along with a cash payment. The deal is expected to close around December 18, 2025, subject to customary conditions.
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE – Sarepta announces completion of the confirmatory tri
Sarepta Therapeutics reported its third-quarter 2025 financial results and announced the completion of its ESSENCE study evaluating the efficacy of AMONDYS 45 and VYONDYS 53 for Duchenne muscular dystrophy. Although the study did not meet statistical significance, it indicated positive trends for the therapies, especially after excluding data impacted by the COVID-19 pandemic. The company plans to discuss these findings with the FDA to explore a potential traditional approval process based on the observed benefits. Additionally, Sarepta reported solid financial performance and advancements in their gene therapy pipeline.
Read more →SRPTSAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Sarepta Therapeutics, alleging that the company misled investors about the safety and efficacy of its gene therapy, ELEVIDYS, meant to treat Duchenne muscular dystrophy. The lawsuit is related to significant criticisms regarding ELEVIDYS, particularly following reports of patient deaths that have caused substantial stock price declines. Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, are encouraged to connect with the law firm before the August 25, 2025, deadline to be appointed as lead plaintiff.
Read more →SRPTSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT
Sarepta Therapeutics, Inc. is currently facing a lawsuit alleging securities law violations related to its gene therapy product ELEVIDYS. The allegations claim that the company issued false and misleading statements regarding the safety of the therapy and its trial results. These issues reportedly led to significant adverse events that necessitated halting recruitment and dosing in clinical trials. Shareholders are being urged to register for potential recovery as lead plaintiffs before the August 25, 2025 deadline.
Read more →SRPTSAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
A class action lawsuit has been filed against Sarepta Therapeutics, alleging that the company misled investors about its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy. The claims include that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and that misleading statements led to inflated expectations about its approval and revenue potential. Following reports of serious adverse events, including patient deaths, Sarepta's stock price experienced substantial declines. Investors have until August 25, 2025, to apply to be lead plaintiffs in the lawsuit.
Read more →SRPTSarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT
Sarepta Therapeutics, Inc. is facing a class action lawsuit regarding alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025. The complaint alleges that the company's gene therapy ELEVIDYS has unreported safety risks and that trial protocols failed to detect severe side effects. As a result, the lawsuit claims that investors were misled about the therapy's safety and regulatory approval process. Investors have until August 25, 2025, to apply to become lead plaintiffs in the case.
Read more →SRPTSarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 25, 2025 Deadline to file Lead Plaintiff Motion
Sarepta Therapeutics, Inc. is currently under scrutiny due to a class action lawsuit from investors alleging misleading statements concerning the safety and efficacy of its gene therapy product, ELEVIDYS. Significant adverse effects, including patient deaths from acute liver failure, prompted regulatory investigations and a reevaluation of clinical trial protocols. These developments have led to substantial declines in the company's stock price and have jeopardized the approval process for ELEVIDYS. Investors are being encouraged to contact the Portnoy Law Firm for potential recovery of losses related to these issues.
Read more →SRPTSarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman
Sarepta Therapeutics is facing significant challenges as its gene therapy ELEVIDYS was rejected by European regulators due to inadequate evidence of benefits for Duchenne muscular dystrophy patients. Additionally, the company is under scrutiny from a securities class action lawsuit alleging misrepresentation of the therapy's safety and efficacy. Recent incidents of patient deaths during clinical trials have led to further concerns and a decline in investor confidence, prompting legal actions to determine the extent of misleading information provided by the company.
Read more →SRPTSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman
Sarepta Therapeutics (SRPT) has faced a severe setback with the European Medicines Agency's (EMA) recommendation to refuse marketing authorization for its drug ELEVIDYS, intended for Duchenne muscular dystrophy. Following this decision, the company's stock price declined significantly, compounded by reports of patient deaths linked to the treatment. A securities class action lawsuit has been filed against the company, alleging it misled investors about the drug's safety and efficacy. In response, Sarepta is restructuring to cut costs, which includes a 36% reduction in its workforce. These developments have left investors concerned about the future of the company's drug pipeline and financial stability.
Read more →SRPTSAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline
Sarepta Therapeutics, Inc. is facing a securities fraud lawsuit filed by Bleichmar Fonti & Auld LLP due to potential violations of federal securities laws. The lawsuit arises amid alarming reports that Elevidys, a treatment for Duchenne muscular dystrophy, has been associated with fatal liver failures in patients. Following these events, Sarepta's stock has experienced considerable declines, reflecting investor concerns over the company's disclosures about the drug's safety. Investors are encouraged to engage with the lawsuit before the August 25 deadline to participate.
Read more →SRPTSarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Sarepta Therapeutics, Inc. is currently facing a class action lawsuit due to alleged securities fraud impacting investors from June 22, 2023, to June 24, 2025. The complaint specifically focuses on the company's gene therapy, ELEVIDYS, claiming it posed significant safety risks that were not disclosed. Additionally, the lawsuit indicates that trial protocols failed to detect severe adverse effects, which could jeopardize the therapy's approvals and prompt regulatory attention. Investors are encouraged to participate in the case with potential compensation without out-of-pocket costs.
Read more →SRPTSAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Sarepta Therapeutics, focusing on allegations that the company misled investors regarding the safety and revenue potential of its gene therapy, ELEVIDYS. The lawsuit arises during a period marked by serious safety incidents, including patient deaths, which have significantly affected the company's stock price. Sarepta recently halted recruitment for ELEVIDYS trials amid growing regulatory scrutiny and negative findings about the treatment. The FDA is currently investigating the risks associated with ELEVIDYS, adding to the legal troubles and investor concerns surrounding the company.
Read more →SRPTSarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.
Sarepta Therapeutics is currently the subject of a class action lawsuit concerning its gene therapy product ELEVIDYS, which has allegedly caused significant safety issues and has been linked to patient deaths. Investors who purchased shares from June 22, 2023, to June 24, 2025, have until August 25, 2025, to file a lead plaintiff motion. The lawsuit claims the company made misleading statements regarding the safety and clinical trial protocols for ELEVIDYS, leading to serious regulatory scrutiny and stock price declines. Notably, a patient death attributed to ELEVIDYS and the subsequent regulatory actions have greatly affected investor trust.
Read more →SRPTSAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Sarepta Therapeutics, alleging that the company made misleading statements regarding the safety and revenue outlook of its gene therapy, ELEVIDYS. Key accusations indicate that Sarepta failed to disclose severe safety risks and adverse events, which ultimately led to halting of clinical trials. Recent disclosures of patient deaths after treatment with ELEVIDYS have resulted in significant stock price declines for the company. The case highlights the potential legal ramifications for Sarepta in light of these serious allegations.
Read more →SRPTSarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion
Sarepta Therapeutics, Inc. is facing a class action lawsuit related to allegations of making false statements about its gene therapy product, ELEVIDYS. The lawsuit stems from incidents where patients treated with ELEVIDYS experienced adverse effects, including deaths from acute liver failure. Following the disclosures of these safety concerns, the company's stock has experienced significant declines. Investors have until August 25, 2025, to file a lead plaintiff motion in this case.
Read more →SRPTSAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
Sarepta Therapeutics, Inc. is currently involved in a securities fraud class action lawsuit that alleges misrepresentations regarding the safety of its treatment for Duchenne muscular dystrophy, ELEVIDYS. The lawsuit, filed in the Southern District of New York, targets the company and its senior officers, claiming violations of the Securities Exchange Act of 1934. Shareholders are reminded of an impending deadline to file as lead plaintiffs in this case. Investors may face financial repercussions stemming from the allegations made in the lawsuit.
Read more →SRPTSarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman
Sarepta Therapeutics (SRPT) announced a major restructuring that includes a significant workforce reduction of 500 employees to save about $400 million annually. A black box warning regarding acute liver injury and failure will be added to the label of their gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy. The company is also facing a securities class action alleging misleading disclosures regarding the safety and efficacy of the drug. Additionally, the European Medicines Agency has recommended refusal of marketing authorization for ELEVIDYS due to concerns about its effectiveness, leading to further declines in Sarpta's stock price.
Read more →SRPTSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT
Sarepta Therapeutics, Inc. is facing a class action securities lawsuit led by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged securities fraud. The complaint asserts that the company misled investors regarding the safety of its gene therapy, ELEVIDYS, and the efficacy of its clinical trial protocols. It also indicates that serious safety concerns could halt trial activities and regulatory approvals. Investors who believe they have suffered losses have until August 25, 2025, to participate in the lawsuit.
Read more →SRPTSarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending – Hagens Berman
Sarepta Therapeutics, Inc. experienced a 36% drop in stock prices following the death of a third patient receiving treatment with its gene therapy, ELEVIDYS. The company is also facing a securities class action lawsuit, claiming it misled investors about the safety of its therapies. Regulatory bodies have placed its investigational trials on hold, and analysts have cut their price targets to zero amid growing concerns over the drug's safety. The developments indicate increasing scrutiny and potential financial liabilities for the company.
Read more →SRPTSarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman
Sarepta Therapeutics' stock plummeted by 36% following the reported death of a third patient in clinical trials of its gene therapy drug, ELEVIDYS. This incident comes concurrently with a class action lawsuit alleging that the company misled investors regarding the drug's safety. Regulatory bodies have also intervened, with the FDA placing clinical trials on hold due to safety concerns. As a result, analysts have significantly reduced their price target for Sarepta's shares, compounding the negative outlook for the company.
Read more →SRPTSarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Sarepta Therapeutics, Inc. is facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP, related to alleged fraud committed between June 22, 2023, and June 24, 2025. The complaint highlights significant safety risks associated with its gene therapy ELEVIDYS, including failure to detect severe side effects and the potential for halted trials due to adverse events. Investors are encouraged to assess their eligibility to participate in the lawsuit by the deadline of August 25, 2025.
Read more →SRPTSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT
Sarepta Therapeutics, Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP, which seeks to recover losses for investors affected by alleged fraud between June 2023 and June 2025. The lawsuit claims that the company made false statements regarding the safety of its gene therapy, ELEVIDYS, which is intended for treating Duchenne Muscular Dystrophy. Allegations include that severe side effects were not properly detected and that this could lead to halted trials and increased regulatory scrutiny. Investors have until August 25, 2025, to act as lead plaintiffs in the case.
Read more →SRPTSarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label • After strategic review, Sarepta focuses pip
Sarepta Therapeutics has announced a strategic restructuring plan focused on prioritizing high-impact programs and achieving sustainable growth. This restructuring is expected to yield approximately $400 million in annual cost savings and includes a significant reduction in workforce. The company also updated the ELEVIDYS label to include a black box warning due to safety considerations while emphasizing the continued strength of its Duchenne muscular dystrophy product portfolio, which reported significant revenues. Future efforts will focus on enhancing their siRNA platform and progressing development for various rare genetic diseases.
Read more →SRPTSarepta Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT
Sarepta Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its ELEVIDYS gene therapy for Duchenne muscular dystrophy. The complaint claims that the therapy posed significant safety risks and that trial protocols failed to detect severe side effects. As a result, the company may have to halt recruitment and dosing in trials, potentially attracting regulatory scrutiny. Shareholders are encouraged to participate in the lawsuit, which has a lead plaintiff deadline of August 25, 2025.
Read more →SRPTSarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT
Sarepta Therapeutics, Inc. is facing a securities fraud class action lawsuit filed on behalf of shareholders who purchased shares of the company during the class period from June 22, 2023, to June 24, 2025. The lawsuit alleges that the company issued misleading statements regarding the safety of its gene therapy, ELEVIDYS, which has been implicated in serious adverse events. Shareholders are encouraged to register with the Gross Law Firm, which is managing the class action, before the August 25, 2025 deadline to potentially recover losses associated with these statements.
Read more →SRPTSarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit
Robbins LLP has issued a reminder to Sarepta Therapeutics stockholders regarding a class action lawsuit filed for investors who purchased shares between June 22, 2023, and June 24, 2025. The lawsuit accuses Sarepta of misleading stakeholders about the safety of its gene therapy drug, ELEVIDYS, particularly following reports of severe adverse events and patient fatalities. This has led to significant stock price declines and regulatory scrutiny. The firm is currently seeking lead plaintiffs to act on behalf of affected investors.
Read more →SRPTSAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Sarepta Therapeutics, relating to alleged misleading statements about its gene therapy, ELEVIDYS. The lawsuit encompasses all individuals who purchased Sarepta securities between June 22, 2023, and June 24, 2025. Concerns have been raised about ELEVIDYS' safety and the company's failure to disclose serious risks following reported patient deaths. As a result, Sarepta has faced significant stock price declines and increased regulatory scrutiny.
Read more →SRPTSAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a class action lawsuit against Sarepta Therapeutics, Inc. on behalf of investors who suffered losses from June 22, 2023, to June 24, 2025. The lawsuit alleges that the company misrepresented safety risks associated with its drug, ELEVIDYS, intended for treating Duchenne muscular dystrophy. Shareholders can apply to be lead plaintiffs but may remain as absent class members if they choose not to participate. The law firm offers no fees or expenses for representation, operating on a contingency fee basis.
Read more →SRPTSarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Sarepta Therapeutics, Inc. is currently under investigation by the Portnoy Law Firm for possible securities fraud, following a drop of 27% in their stock price. This decline was triggered by the report of a patient death related to the company's gene therapy product, Elevidys, which treats Duchenne muscular dystrophy. The patient reportedly suffered from acute liver failure, raising concerns within the medical community regarding the safety of the treatment. The law firm is encouraging investors who may have lost money to contact them for a potential class action lawsuit.
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments – Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over t
Sarepta Therapeutics announced strong financial results for the fourth quarter and full-year 2024, highlighting a 75% increase in net product revenues, totaling $638.2 million. The company successfully launched its gene therapy ELEVIDYS, achieving significant net income. Looking forward to 2025, Sarepta expects continued growth with projected net product revenues between $2.9 billion and $3.1 billion. It is also poised to achieve several key clinical milestones this year related to its gene therapy pipeline.
Read more →SRPTSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceedi
Sarepta Therapeutics reported preliminary fourth-quarter and full-year 2024 net product revenue, totaling $638.2 million and $1.79 billion respectively. The growth for the fourth quarter represented a 75% increase year-over-year, and the company exceeded its guidance by over $60 million. Notably, its therapeutic product ELEVIDYS saw a remarkable 112% growth from the prior sequential quarter. This performance reflects Sarepta's commitment to providing precision genetic medicine for rare diseases as they head into 2025.
Read more →SRPTSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue – Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023 – Preliminary E
Sarepta Therapeutics has announced preliminary net product revenue of $1.145 billion for 2023, surpassing expectations. The company's gene therapy product, ELEVIDYS, is projected to generate significant revenue, contributing to the strong financial outlook. However, these results are preliminary and may be subject to change before the final financial report is released in late February 2024. Additionally, there are ongoing safety concerns associated with ELEVIDYS that could impact future usage and approval.
Read more →SRPTSarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy ELEVIDYS (delandistrogene moxeparvovec-rokl) is approved for the treatment of ambulatory pediatric pati
Sarepta Therapeutics announced the FDA's accelerated approval of ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy. The treatment is designed for ambulatory pediatric patients aged 4 to 5 years and targets the underlying genetic cause of the disease by introducing a micro-dystrophin. Despite its groundbreaking potential, the approval comes with risks, including serious liver injuries and immune reactions. A confirmatory trial, EMBARK, is ongoing to validate the clinical benefits observed in earlier studies.
Read more →SRPTThis presentation contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” 
Sarepta Therapeutics, Inc. detailed its forward-looking statements regarding the launch of its therapy ELEVIDYS for Duchenne muscular dystrophy. The company outlined its expectations for future operations, including revenue targets of $925 million for 2023 and potential impacts related to treatment efficacy. However, several risks were noted, notably the uncertainty surrounding FDA approval for label expansion and potential regulatory hurdles in clinical trials. Sarepta remains committed to its research goals while cautioning against assumptions based on these forward-looking statements.
Read more →SRPTSarepta Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Sarepta Therapeutics, Inc. regarding potential securities fraud, prompting a call for affected investors to come forward. This news follows a significant drop in Sarepta's stock price after the FDA decided to hold an advisory committee meeting regarding the company's SRP-9001 therapy. The firm encourages investors who sustained losses to contact them for potential recovery options. Legal representation will be offered at no cost to the investors.
Read more →SRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics announced the granting of equity awards to 40 new employees as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include options to purchase 41,125 shares and 22,100 restricted stock units, with specific vesting schedules tied to continued employment. This move reflects Sarepta's commitment to expanding its workforce in the field of precision genetic medicine.
Read more →SRPTSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
Sarepta Therapeutics reported preliminary net product revenues of $235.5 million for Q4 2022 and $843.3 million for the full year. The company anticipates exceeding its revised revenue guidance, supported by its RNA-based therapies. However, these figures are preliminary and unaudited, with final results expected in February 2023.
Read more →SRPTSarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The presentation will showcase the company's advancements in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. A Q&A session will follow the presentation, which will also be available via live webcast.
Read more →SRPTSarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
Sarepta Therapeutics announced that the FDA has accepted its Biologics License Application for SRP-9001, a gene therapy aimed at treating Duchenne muscular dystrophy. The therapy, which has been granted Priority Review, is designed to address the underlying cause of the disease by delivering a functional dystrophin gene. The regulatory action date is set for May 29, 2023, and positive clinical data supports its efficacy and safety.
Read more →SRPTSarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Sarepta Therapeutics announced that its senior management will participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 1, 2022. The event will be held virtually and will be accessible via live webcast. The company is recognized for its leadership in developing precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy.
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
Sarepta Therapeutics announced its third quarter 2022 financial results, highlighting a 24% increase in net product revenue to $207.8 million. The company submitted a Biologic License Application for its gene therapy SRP-9001 aimed at treating Duchenne muscular dystrophy. Despite these advancements, Sarepta reported a substantial net loss of $257.7 million for the quarter.
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2022 Financial Results
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022. Subsequ
Read more →SRPTSarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic medicine portfolio at the 27th International Hybrid Annual Congress of the World M
Read more →SRPTSarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) fo
Read more →SRPTSarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the pricing of $980.0 million aggregate principal amount of convertible senior unsecured notes that will matu
Read more →SRPTSarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
– With current cash and projected revenue, offering is expected to fund operations to profitability CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it
Read more →SRPTSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
- Recipients include 15 individuals living with Duchenne and five siblings in Duchenne families CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced twenty recip
Read more →SRPTSarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 (vesleteplirsen),
Read more →SRPTSarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcar
Read more →SRPTSarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
- Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications - The MyoAAV platform is a potential breakthrough in genetic medicine deli
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
- Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million - Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year - Increased fu
Read more →SRPTSarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced its intent to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandis
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequent
Read more →SRPTSarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
Sarepta and its partner Roche present new results and analyses at the International Congress on Neuromuscular Diseases (ICNMD), which demonstrate that SRP-9001 shows consistent, statistically significant functional benefits in individuals with Duchenne versus a propensity-weighte
Read more →SRPTSarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET
CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 at 8:30am Eastern Time, the Company will host a webcast and conference call to
Read more →SRPTSarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
- Sarepta to host conference call at 4:15 p.m. Eastern time CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA)
Read more →SRPTSarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare
Read more →SRPTSarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers an
Read more →SRPTSarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 0
Read more →SRPTSarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, May 4, 2022. Subsequentl
Read more →SRPTSarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program
Application website is now open for the 2022 Scholarship Program For the 2022-2023 academic year, the scholarship program has expanded to include two groups: one for individuals living with Duchenne and another for siblings in Duchenne families. CAMBRIDGE, Mass., March 08, 2022
Read more →SRPTSarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences: Co
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million and $701.9 million, respectively Net product revenues for the fourth quarter and full-year 2021 totaled $178.7 million and
Read more →SRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 202
Read more →SRPTSarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
Collaboration combines Sarepta’s proprietary gene editing technologies and GenEdit’s non-viral delivery platform to create new genetic medicines for patients with neuromuscular diseases Initial results from the ongoing research collaboration have demonstrated delivery to muscle
Read more →SRPTSarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscula
Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy Participants from the placebo crossover group i
Read more →SRPTSarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Presentation on Monday, Jan. 10, 2022, to include topline results from Part 2 of Study SRP-9001-102 CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that seni
Read more →SRPTSarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company’s board CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for r
Read more →SRPTSarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
Gilmore O’Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022 CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today annou
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior year In light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million CA
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequ
Read more →SRPTSarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the p
Read more →SRPTSarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stoc
Read more →SRPTSarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021. Sarepta expects its net product
Read more →SRPTSarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
Results presented at ‘Micro-dystrophin Day’ highlight breadth, depth and strength of the clinical evidence to date for SRP-9001 in treating Duchenne muscular dystrophy; tolerability profile remains consistent across treated patients Results from Study SRP-9001-101 found that SRP
Read more →SRPTSarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- Sarepta to host “SRP-9001 Micro-dystrophin R&D Day” at 8:30 a.m. Eastern Time on Monday, Oct. 11, 2021 CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the
Read more →SRPTSarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
Center dedicated to research and development activities to advance Sarepta’s industry-leading, multi-platform pipeline The Center encompasses 85,000 square feet of space, tripling Sarepta’s footprint in Ohio CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeuti
Read more →SRPTSarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021 CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced pre
Read more →SRPTSarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA - Company Anticipates Part B of MOM
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA CAMBRIDGE, Mass., September 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:S
Read more →SRPTSarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021. This year’s presen
Read more →SRPTSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced fifteen recipients of Route 79, The Duchenne Scholarship Program. This is the fourth year of the scholarship
Read more →SRPTSarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
– Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses – Sarepta’s unrivaled portfolio of investigational gene therapies for LGMD offers the potential to address six LGMD subtypes, which together represent more than 7
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
Sarepta announces successful completion of end-of-phase-2 meeting for SRP-9001 micro-dystrophin with FDA’s Office of Tissues and Advanced Therapies (OTAT) and plans to initiate pivotal trial, SRP-9001-301 (Study 301 or EMBARK), in September of 2021 Net product sales for the seco
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subseque
Read more →SRPTSarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material - Re
Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) - Sarepta Thera
Read more →SRPTSarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to p
Read more →SRPTSarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today repor
Read more →SRPTSarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 - Results suggest a highly potent next-generation t
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 CAMBRIDGE, Mass., May 3, 2021 (GLOBE NEWSWIRE) - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in preci
Read more →SRPTSarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to p
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequentl
Read more →SRPTSarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Sarepta) (Nasdaq:SRPT) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to 2,000,000 shares of Sarept
Read more →SRPTSarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
-- Application website is now open for the 2021 Scholarship Program -- -- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:S
Read more →SRPTSarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured by western blot -- -- Mean NSAD score improvement of 5.7 points from baseline
Read more →SRPTSarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
-- Ten abstracts, including four podium presentations, reflect Sarepta’s ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions -- CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) --
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference – – Fourth quarter 2020 net product sales increased approximately 23% over the fourth qua
Read more →SRPTSarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
-- AMONDYS 45 is Sarepta’s third RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately -- -- Information for patients and clinicians is available at www.SareptAssist.com -- CAMBRIDGE, Mass., F
Read more →SRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021
Read more →SRPTSarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
The four winning lesson plans are now available on sharemylesson.com Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASD
Read more →SRPTSarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for an exclusive license to Genevant’s LNP technology for four neuromuscular indicat
Read more →SRPTForward-looking Statements This presentation contains forward-looking statements. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "antici
Our mission continues. DOUGLAS INGRAM President and Chief Executive Officer JP Morgan 39th Annual Healthcare Conference 2021 January 11, 2021 Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease. At
Read more →SRPTSarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday,
Read more →SRPTSarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy -- Study met the primary biological endpoint
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy -- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-tre
Read more →SRPTSarepta Therapeutics Announces Executive Management Changes
-- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to retire from Sarepta -- Ryan Brown named interim general counsel CAMBRIDGE, Mass., Dec
Read more →SRPTSarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping,
Read more →SRPTSarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to prese
Read more →SRPTSarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual C
Read more →SRPTSarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
-- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information submitted by employees to independent research company -- CAMBRIDGE, Mass., No
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
– Net product sales of $121.4 million, a 23% increase over same quarter of prior year – CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for
Read more →SRPTSarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
-- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical dosing is expected to begin before the end of 2020 -- CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in pr
Read more →SRPTSarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financial results after the Nasdaq Global Market closes on Thursday, November 5, 2020. Subseque
Read more →SRPTSarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
-- Continued functional improvements were observed at 18 months in the low-dose cohort -- -- First look at functional outcomes in high-dose cohort found improvements 6 months after administration -- -- Results in both cohorts continue to reinforce safety and tolerability profil
Read more →SRPTSarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
--Results demonstrate continued safety and tolerability of SRP-9001 in four participants with Duchenne -- --All four participants demonstrated improvements in NSAA scores compared to baseline and showed a durable response two years after administration of SRP-9001 -- CAMBRIDGE,
Read more →SRPTSarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy CAMBRIDGE, Mass., Sept. 9, 2020 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, to
Read more →SRPTSarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
-- FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 -- -- FDA has indicated it does not currently plan to hold an advisory committee meeting to discuss the application -- -- Received FDA's conditional approval of AMONDYS 45™ as brand name
Read more →SRPTSarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research f
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
– Net product sales of $111.3 million, an 18% increase over same quarter of prior year – CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2020. Subseque
Read more →SRPTSarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SRP-9001 (AAVrh74.MHCK7
Read more →SRPTSarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the launch of Rare Lessons, a Sarepta-led lesson planning competition intended to promote the development and
Read more →SRPTSarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
-- Exclusive worldwide license enables Sarepta to develop and promote imlifidase as a pre-treatment for gene therapy in Duchenne and Limb-girdle muscular dystrophy patients who have pre-existing antibodies to AAV -- CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta The
Read more →SRPTSarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy Mahatme, Sarepta’s executive vice president, chief financial officer and chief busines
Read more →SRPTSarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
-- Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne -- -- Casimersen is the third exon-skipping medicine using the Company’s proprietary PMO RNA-based platform -- CAMBRIDGE, Mass., June 26, 2020 (GLOBE
Read more →SRPTSarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
- Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies - - Two-year, global research and option agreement covers up to five neuromuscular targets - - Codiak is eligible to recei
Read more →SRPTSarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
– Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies – CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT), the leader
Read more →SRPTSarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
-- Results at one year demonstrate continued safety and tolerability of SRP-9001 micro-dystrophin gene therapy in four patients with Duchenne muscular dystrophy -- -- Confirmed vector transduction and functional improvements maintained through one year -- CAMBRIDGE, Mass., June
Read more →SRPTSarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E -- In post-treatment muscle biopsies, clinical trial participant
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E -- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase
Read more →SRPTSarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, June 8, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to prese
Read more →SRPTSarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healt
Read more →SRPTSarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
-- Agreement leverages Sarepta’s leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno’s CapsidMap artificial intelligence platform to design AAV vectors -- CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), t
Read more →SRPTSarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
– Net sales of $100.4 million, a 15% increase over same quarter of prior year – – $2.2 billion of cash on hand to drive clinical programs without distraction from COVID-19 pandemic – CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), th
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2020. Subsequentl
Read more →SRPTSarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the
Read more →SRPTSarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today a
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three and twelve months ended December 31, 2019. “The Sarepta team made great progre
Read more →SRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2019 financial results after the Nasdaq Global Market closes on Wednesday, February 2
Read more →SRPTSome see slow and steady scientific progress. We see a revolution. DOUG INGRAM President and CEO J.P. Morgan 38th Annual Healthcare Conference
Some see slow and steady scientific progress. We see a revolution. DOUG INGRAM President and CEO J.P. Morgan 38th Annual Healthcare Conference January 13, 2020 LIAM Living with MPS IIIA ADVANCED CLINICAL DEVELOPMENT BROADENED REACH EXPANDED ALLIANCES DEEPENED PIPELINE STRENGTHEN
Read more →SRPTSarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its Board of Directors, effective today. Dr. Martin brings decades o
Read more →SRPTSarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, Cal
Read more →SRPTSarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in cash and $400 million in Sarepta stock, priced at $158.59 per share of common s
Read more →SRPTSarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds managed by Pharmakon Advisors, LP, that provides Sarepta with
Read more →SRPTSarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
-- VYONDYS 53 is Sarepta’s second RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately -- -- Information for patients and clinicians is available at www.SareptAssist.com -- CAMBRIDGE, Mass.,
Read more →SRPTSarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
-- Agreement leverages StrideBio’s novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta’s early stage gene therapy pipeline – -- Sarepta granted an exclusive license to four CNS targets, on which StrideBio will lead early research and develop
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019. “EXONDYS 51® (eteplirsen) enjoyed another strong quarter, wit
Read more →SRPTSarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, Nov. 12
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2019 financial results after the Nasdaq Global Market closes on Thursday, November 7, 2019. Subseque
Read more →SRPTSarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data presented earlier in 2019 -- CAMBRIDGE, Mass., Oct. 04, 2019
Read more →SRPTand then advance our SRP-9003 program, along with our other five LGMD programs, as rapidly as possible ; Sarepta continui ng to build an enduring gene therapy model created to design, develop and bring to the medical and
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy -- Improvements on functional measures seen in all three participants -- -- Significant reduction
Read more →SRPTSarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links belo
Read more →SRPTSarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4, 2019 at 8:00 a.m. Eastern Time (ET), it will host a webcast and conference call to p
Read more →SRPTSarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday,
Read more →SRPTletter and find an expeditious pathway forward for the approval of golodirsen, and our immediate request for a meeting with the FDA. These forward-looking statements involve risks and uncertainties, many of which are bey
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application CAMBRIDGE, Mass., August 19, 2019 (GLOBE NEWSWIRE) - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare di
Read more →SRPTSarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding th
Read more →SRPTSarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS) CAMBRIDGE, Mass., August 8, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, was informed earlier
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2019. “As we pass through mid-2019, we are very pleased to announc
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2019. Subseque
Read more →SRPTSarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday,
Read more →SRPTSarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
--Expands pipeline with 6th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), th
Read more →SRPTSarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2019. “Having built out our multi-platform portfolio of
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019. Subsequently,
Read more →SRPTSarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today stated that its previously announced positive clinical data from the Company’s Limb-girdle muscular dystrophy (LGMD) Ty
Read more →SRPTSarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study -- Interim analysis found statistically significant increase in dystrophin production as measured by west
Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study -- Interim analysis found statistically significant increase in dystrophin production as measured by western blot in casimersen-treated participants compared to bas
Read more →SRPTForward-Looking Statements This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anti
Clinical Update: Micro-dystrophin Study-101 Louise Rodino-Klapac, Ph.D. Senior Vice President, Gene Therapy Sarepta Therapeutics, Inc. Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking statements." Any statements that are not statements of his
Read more →SRPTSarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8:00 a.m. Eastern Time (ET) on Monday, March 25, 2019. On the ca
Read more →SRPTSarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares of its common stock at
Read more →SRPTSarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock
Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock CAMBRIDGE, Mass., March 5, 2019 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sel
Read more →SRPTSarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications
Read more →SRPTSarepta Exercises Option to Acquire Myonexus Therapeutics
-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) -- CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the lea
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments RNA Franchise Advances -Reported EXONDYS 51 (eteplirsen) net sales of $84.4M for the quarter and f
Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments RNA Franchise Advances -Reported EXONDYS 51 (eteplirsen) net sales of $84.4M for the quarter and full-year net sales of $301.0M, in line with guidance- -Fi
Read more →SRPTSarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 20% measure for success -- -- Robust expression was als
Read more →SRPTSarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that commencing at 8:00 a.m. Eastern Time (ET) on Wednesday February 27, 2019, it will host a webcast and conference
Read more →SRPTSarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- FDA Grants Priority Review Status -- -- Regulatory Action Date is August 19, 2019 -- -- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- S
Read more →SRPTSarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
-- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs -- -- Aldevron,
Read more →SRPTSarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California o
Read more →SRPTFORWARD LOOKING STATEMENTS This presentation contains "forward looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not hi
37th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, January 7, 2019 Doug Ingram President and CEO, Sarepta Therapeutics, Inc. Exhibit 99.1 FORWARD LOOKING STATEMENTS This presentation contains "forward looking statements" within the meaning of the safe harbor pro
Read more →SRPTSarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- -- Submission represents ongoing advancement of the company’s proprietary PMO RNA-based platform -- CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEW
Read more →SRPTSarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. Dr. Gray has more than three decades of bio
Read more →SRPTSarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 3,817,000 shares of its common stock at a
Read more →SRPTSarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14,
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
-- Third quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today reported financial results for the
Read more →SRPTSarepta Therapeutics, Inc. Consolidated Balance Sheets (unaudited, in thousands, except share and per share data) As of
Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments -- Third quarter 2018 EXONDYS 51 (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass., October 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018
CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will report third quarter 2018 financial results after the Nasdaq Global Market closes on Wednesday, October 24, 2018. Subsequen
Read more →SRPTSarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
-- Expands Sarepta’s portfolio to as many as 14 gene therapy programs -- -- Mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, is a rare, severe and fatal inherited neurodegenerative lysosomal storage disorder -- -- The pivotal gene therapy stud
Read more →SRPTSarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies
CAMBRIDGE, Mass., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that it has ente
Read more →SRPTSarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder
-- Furthers the Company’s strategy to expand neuromuscular gene therapy franchise -- -- CMT is a group of hereditary, degenerative nerve diseases that in addition to causing extraordinary pain, can greatly impact peripheral motor skills and profoundly limit the ability to walk o
Read more →SRPTSarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy
-- Biopsy of fourth patient showed robust micro-dystrophin expression as measured by Western blot and immunohistochemistry -- -- Positive functional improvements shown across all measures -- -- No serious adverse events (SAEs) observed -- CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE
Read more →SRPTSarepta Therapeutics Announces that at the 23 rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystroph
Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy
Read more →SRPTSarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Children’s Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Cu
Read more →SRPTSarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food a
Read more →SRPTSarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
-- Relying upon Scientific Advisory Group input, Sarepta will seek further scientific advice from European Medicines Agency on a possible path to bring eteplirsen to patients in Europe -- CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SR
Read more →SRPTSarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Na
Read more →SRPTSarepta Therapeutics to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases and other rare diseases, today
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today reported financial result
Read more →SRPTSarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools
-- Sarepta expands its presence in gene therapy and broadens its reach with license to up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s gene therapy candidate for Pompe Disease and options to two additional candidates -- -- Sarepta wil
Read more →SRPTSarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events
-- Out-of-specification lot resulted from the presence of trace levels of DNA fragment in research-grade raw material plasmid sourced from third-party manufacturer -- -- Fragment fully characterized; preliminary testing and analysis indicates no safety signals -- -- Subject to
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018
CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report second quarter 2018
Read more →SRPTSarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Pati
Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy -- Biopsies performed
Read more →SRPTSarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply
-- The partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch and other neuromuscular programs in the pipeline -- -- Hybrid model enables Sarepta to maintain control over process development, while leveraging Brammer Bio’s world-c
Read more →SRPTSarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018
-- Event to be Webcast Live – CAMBRIDGE, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, w
Read more →SRPTSarepta Therapeutics Appoints Gilmore O’Neill, M.B., M.M.Sc. as Chief Medical Officer
CAMBRIDGE, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced the appointment
Read more →SRPTSarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
-- Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from bench to human clinical development -- -- Served as a principal investigator and c
Read more →SRPTSarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments First quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of $64.6 million Sarepta signs exclusive partnership and
Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments First quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of $64.6 million Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expan
Read more →SRPTSarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies
-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise -- -- The program is designed, if successful, to offer first-ever corrective treatments for five distinct forms of Limb-girdle muscular dystrophy (LGMD) -- -- Sarepta is granted exclusiv
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Developments on May 3, 2018
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018
Read more →SRPTSarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today the launch of i
Read more →SRPTSarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 The Company met
Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 with the FDA Division of Neurology Products in February to obtain guidance
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments Fourth quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of $57.3 million Cash and investmen
Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Fourth quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of Cash and investment balance of $1.1 billion as of December 31, 2017 CAMBRIDGE, Mass., March 1, 2018 (G
Read more →SRPTSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report fourth quarter and f
Read more →SRPTSarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced that management
Read more →SRPTSarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51 (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 – $305 million -- -- 16 programs in development -- SAN FRANCISCO, Jan. 08, 2018 (G
Read more →SRPTSarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management
Read more →SRPTFORWARD-LOOKING STATEMENTS This presentation contains "forward looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not hi
Precision genetic medicine for rare neuromuscular diseases 36TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE SAN FRANCISCO, CALIFORNIA JANUARY 8, 2018 NASDAQ: SRPT Jackson Exhibit 99.1 2 FORWARD-LOOKING STATEMENTS This presentation contains "forward looking statements" within the me
Read more →SRPTSarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
CAMBRIDGE, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that the pulmon
Read more →SRPTSarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the election of
Read more →SRPTSarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the exercise in
Read more →SRPTSarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the pricing of
Read more →SRPTSarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the U.S. Fo
Read more →SRPTSarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024 Chief executive officer indicates interest in purchasing $2 million of shares of Sarepta s common stock
Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024 Chief executive officer indicates interest in purchasing $2 million of shares of Sarepta s common stock CAMBRIDGE, Mass., November 7, 2017 (GLOBE NEWSWIRE) Sarepta Therapeutics
Read more →SRPTSarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
-- Nationwide Children’s Hospital to initiate a Phase 1/2a clinical trial at potentially therapeutic doses in children with DMD by mid-November 2017 -- -- First micro-dystrophin gene therapy program in clinical development for DMD -- CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSW
Read more →SRPTSarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, and Nationwide Children’s Hospi
Read more →SRPTSarepta Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management
Read more →SRPTSarepta Therapeutics Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR/Cas9 Technology to Develop New Treatments for Duchenne Muscular Dystrophy (DMD)
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that it has sig
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments Third quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of $46 million Company raises annual 2017 revenue guidan
Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments Third quarter 2017 EXONDYS 51 (eteplirsen) total net revenues of $46 million Company raises annual 2017 revenue guidance to between $150 million and $155 million CAMBRIDGE, Ma
Read more →SRPTSarepta Therapeutics to Announce Third Quarter 2017 Financial Results and Recent Corporate Developments on October 25, 2017
CAMBRIDGE, Mass., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will report third quarter 2017
Read more →SRPTSarepta Therapeutics to Present at the 22nd International Annual Congress of the World Muscle Society
CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will present a total of six po
Read more →SRPTSarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer
CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the appointmen
Read more →SRPTSarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day
CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will ring Nasdaq’s Closing Bel
Read more →SRPTSarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053)
-- Study achieved statistical significance on all primary and secondary biological endpoints -- -- Results further validate the Company’s exon-skipping platform for the treatment of DMD -- CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:S
Read more →SRPTSarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will visit the Nasdaq MarketSite in T
Read more →SRPTSarepta Therapeutics to Present at Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management
Read more →SRPTSarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications
CAMBRIDGE, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the publication
Read more →SRPTSarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today ann
Read more →SRPTSarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock CAMBRIDGE, MA
Sarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock CAMBRIDGE, MA July 24, 2017 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeu
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments Achieved net revenue of $35 million for the second quarter 2017 Increased revenue guidance range to $125 $130 million
Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments July 19, 2017 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RN
Read more →SRPTSarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
CAMBRIDGE, Mass., July 19, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Clinigen Group plc’s (
Read more →SRPTSarepta Therapeutics Secures $100 Million in Debt Financing
Sarepta Therapeutics Secures $100 Million in Debt Financing CAMBRIDGE, Mass., July 18, 2017 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics
Read more →SRPTSarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation Agreement terms resolve global patent proceedings regardin
Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation Agreement terms resolve global patent proceedings regarding Sarepta s sale of EXONDYS 51 (eteplirsen) and future Duc
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, will repo
Read more →SRPTSarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer Mr. Ingram was the President of Allergan, Inc.
Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer Mr. Ingram was the President of Allergan, Inc. CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company
Read more →SRPTSarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover
CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today ann
Read more →SRPTSarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass. and EVRY, France, June 21, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular di
Read more →SRPTSarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announced
Read more →SRPTSarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments First quarter 2017 EXONDYS 51 total net revenues of $16.3 million Company anticipates net revenues for the year will e
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments First quarter 2017 EXONDYS 51 total net revenues of $16.3 million Company anticipates net revenues for the year will exceed $95 million CAMBRIDGE, Mass., April 27, 2017 (GLOBE
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017
CAMBRIDGE, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, will report f
Read more →SRPTSarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted an eq
Read more →SRPTSarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer
CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announc
Read more →SRPTSarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board
CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announc
Read more →SRPTSarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference
CAMBRIDGE, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today provide
Read more →SRPTSarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Bost
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE) February 28, 2017 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discover
Read more →SRPTSarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Sale of PRV Provides a Significant Infusion of Non-Dilutive Capital CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Sale of PRV Provides a Significant Infusion of Non-Dilutive Capital CAMBRIDGE, Mass. (BUSINESS WIRE) February 21, 2017 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative
Read more →SRPTForward-looking statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not hi
RNA-targeted Precision Medicine for Duchenne Muscular Dystrophy JANUARY 10, 2017 NASDAQ: SRPT Exhibit 99.1 Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigat
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE) October 27, 2016 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today reported
Read more →SRPTSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy Sarepta and Summit col
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy Cambridge, MA, and Oxford, UK, 4 October 2016 Sarepta Therapeutics (NASDAQ: SRP
Read more →SRPTSarepta Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, MA
Sarepta Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, MA September 21, 2016 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other cond
Read more →SRPTSarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical - Final refusal of BioMarin s interfering claims facilitates
Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical CAMBRIDGE, Mass. (BUSINESS WIRE) Sep. 20, 2016 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RN
Read more →SRPTSarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51 (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51 EXONDYS 51 the first
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51 (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51 EXONDYS 51 the first DMD treatment approved in the US, targets dystrophin def
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE) July 19, 2016 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results
Read more →SRPTSarepta Therapeutics Announces Proposed Offering CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces Proposed Offering CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 8, 2016 Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends
Read more →SRPTSarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 6, 2016 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S.
Read more →SRPTSarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE)
Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments CAMBRIDGE, Mass. (BUSINESS WIRE) May 5, 2016 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results and Recent Corporate Developments - Announced
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results and Recent Corporate Developments - Announced May 26, 2016 PDUFA goal date for eteplirsen - Ended year with $204 million cash, cash equivalents, and marketable securities CAMBRIDGE, Mass. (BUSIN
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments - Well capitalized with $111 million in cash and other investments at quarter end, with an additional $120 million rai
Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments - Well capitalized with $111 million in cash and other investments at quarter end, with an additional $120 million raised post-quarter end CAMBRIDGE, Mass. (BUSINESS WIRE) Nove
Read more →SRPTSarepta Therapeutics Investor Update
Sarepta Therapeutics Investor Update SVP, Chief Medical Officer Interim Chief Executive Officer Sarepta Therapeutics Cambridge, Massachusetts, USA Forward-Looking Statement contains forward-looking statements. These forward-looking statements generally can be identified by the
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments - NDA submission to FDA for eteplirsen completed on
Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments - NDA submission to FDA for eteplirsen completed on June 26, 2015 - - Cash and Other Investments of $158 Million - CAMBRIDGE, Mass. (BUSINESS WIRE) August 6, 2015 Sarepta The
Read more →SRPTSarepta Therapeutics Secures $40 Million in Debt Financing CAMBRIDGE, Mass. (BUSINESS WIRE
Sarepta Therapeutics Secures $40 Million in Debt Financing CAMBRIDGE, Mass. (BUSINESS WIRE June 29, 2015 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it entered into a credit and security agreement with Midc
Read more →SRPTSarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments - Pre-NDA meeting with FDA calendared for second quarter 2015 - - NDA submission for eteplirsen planned for mid-year 2
Sarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments - Pre-NDA meeting with FDA calendared for second quarter 2015 - - NDA submission for eteplirsen planned for mid-year 2015 - - Cash and Other Investments of $167 Million - CAM
Read more →SRPTSarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs Christopher Garabedian Resigns as Chief Executive
Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs Christopher Garabedian Resigns as Chief Executive Officer and Member of the Board Company will host confer
Read more →SRPTSarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments NDA submission for eteplirsen planned for mid-year 2015 - Plan to discuss new data and NDA submission w
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments CAMBRIDGE, MA, February 26, 2015 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results
Read more →SRPTREALIZING THE POTENTIAL OF RNA-BASED TECHNOLOGY JP MORGAN HEALTHCARE CONFERENCE JANUARY 15, 2015 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. These forward-looking statements generall
REALIZING THE POTENTIAL OF RNA-BASED JP MORGAN HEALTHCARE CONFERENCE FORWARD LOOKING STATEMENTS contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as believes or belief, anticipates, plans, expects, will,
Read more →SRPTSarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments -Eteplirsen confirmatory study in ambulatory patients and study in advanced/non-ambulatory patients to begin dosing th
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments -Eteplirsen confirmatory study in ambulatory patients and study in advanced/non-ambulatory patients to begin dosing this month- -New Drug Application submission for eteplirsen
Read more →SRPTSarepta Therapeutics Announces Regulatory Update on Eteplirsen Updated and additional guidance received from FDA on specific data requirements for NDA; FDA states further discussion needed to determine what constitutes a
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Updated and additional guidance received from FDA on specific data requirements for NDA; FDA states further discussion needed to determine what constitutes a complete NDA submission; NDA submission planned for mid-
Read more →SRPTSarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments Progress achieved across eteplirsen clinical studies with patient screening expected to begin this month On track to
Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments Progress achieved across eteplirsen clinical studies with patient screening expected to begin this month On track to submit New Drug Application for eteplirsen by year-end F
Read more →SRPTSarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman - Board of Directors Emphasizes its Full Support of CEO Chris Garabedian
Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman - Board of Directors Emphasizes its Full Support of CEO Chris Garabedian CAMBRIDGE, Mass. July 31, 2014 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, an
Read more →SRPTSarepta Investor and Media Contact: Jim Baker 617.274.4010 jbaker@sarepta.com Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts State-of-the-art 60,000 square foot facili
Sarepta Investor and Media Contact: Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts State-of-the-art 60,000 square foot facility enhances internal manufacturing capability CAMBRIDGE, Mass. May 22, 2014 Sarepta Therapeutics, Inc. (N
Read more →SRPTSarepta Investor and Media Contact: Jim Baker 617.274.4010 jbaker@sarepta.com Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments New Drug Application for eteplirsen plan
Sarepta Investor and Media Contact: Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments New Drug Application for eteplirsen planned for submission to FDA by year end; Multiple eteplirsen clinical studies in broader population of DMD p
Read more →SRPTSarepta Investor Contact: Erin Cox 617.274.4014 ecox@sarepta.com Sarepta Media Contact: Jim Baker 617.274.4010 jbaker@sarepta.com Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen
Sarepta Investor Contact: Sarepta Media Contact: Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014 FDA provides updated guidance on potential early approval pathway for eteplirs
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Rec
Sarepta Investor Contact: Sarepta Media Contact: Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments Clarity on Eteplirsen Confirmatory Trial Design Expected in Coming Weeks 2014 Financial Guidance of $110-120 Million
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer
Sarepta Investor Contact: Sarepta Media Contact: Therapeutics Names Art Krieg, M.D., Chief Scientific Officer CAMBRIDGE, Mass. January 9, 2014 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced Arthur Art Krieg, M.D.,
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com Sarepta Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate D
Sarepta Investor Contact: Sarepta Media Contact: Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate Developments Ongoing discussions with FDA remain a priority to advance eteplirsen program in Duchenne muscular dystrophy; Updated guidance lowers
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate
Sarepta Investor Contact: Sarepta Media Contact: Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate Developments of New Drug Application for Eteplirsen Planned for First Half of 2014 Preparations for Confirmatory Eteplirsen Study and M
Read more →SRPTSarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014 CAMBRIDGE, MA (Marketwired) 07/24/13 Sarepta T
Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014 CAMBRIDGE, MA (Marketwired) 07/24/13 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based t
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com Sarepta Therapeutics Announces At-the-Market Equity Offering Facility CAMBRIDGE, MA
Sarepta Investor Contact: Sarepta Media Contact: Sarepta Therapeutics Announces At-the-Market Equity Offering Facility CAMBRIDGE, MA, July 3, 2013 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, entered into an At-the-Market (ATM) e
Read more →SRPTSarepta Investor Contact: Erin Cox 857.242.3714 ecox@sareptatherapeutics.com Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sareptatherapeutics.com Sarepta Therapeutics Announces First Quarter 2013 Financial Result
Sarepta Investor Contact: ecox@sareptatherapeutics.com Sarepta Media Contact: jbaker@sareptatherapeutics.com Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments Documents Requested by FDA for Accelerated Approval Considerat
Read more →SRPTSarepta Investor Contact: Erin Cox +1.857.242.3714 ecox@sareptatherapeutics.com Sarepta Media Contact: Jim Baker +1.857.242.3710 jbaker@sareptatherapeutics.com UWA Media Contact: Simon Handford +61.8.6488.8187 simon.hand
Sarepta Investor Contact: ecox@sareptatherapeutics.com Sarepta Media Contact: jbaker@sareptatherapeutics.com simon.handford@uwa.edu.au Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duc
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, MA
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, MA, December 12, 2012 Sarepta Therapeutics, Inc. (Nasdaq: SRPT), today announced that it is offering to sell, subject to market
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Recent Corporate Developments Positive 48-Week Results from P
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Recent Corporate Developments Positive 48-Week Results from Phase IIb DMD Study Supports Eteplirsen s Further Development, Regulatory and
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, Chief Financial Officer and Ty Howton Senior Vice President, General
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, Chief Financial Officer and Ty Howton Senior Vice President, General Counsel CAMBRIDGE, MA, November 5, 2012 Sarepta Therapeutics, Inc. (NASDAQ: S
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Receives Notice from Department of Defense for Termination of Ebola Therapeutic Program CAMBRIDGE, MA
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Receives Notice from Department of Defense for Termination of Ebola Therapeutic Program CAMBRIDGE, MA, October 3, 2012 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative R
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Announces At-the-Market Equity Offering CAMBRIDGE, MA
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Announces At-the-Market CAMBRIDGE, MA, September 4, 2012 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, entered into an At-the-Market (ATM) equi
Read more →SRPTSarepta Therapeutics, Inc. [SRPT] to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. [SRPT], a developer of innovative RNA-based therapeutics, will visit the NASDAQ MarketSite in Times Square to celebrate its recent positive 36 week clinical data from its Phase IIb study of eteplirsen for the
Read more →SRPTSarepta Investor and Media Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Second Quarter 2012 Financial Results and Recent Corporate Developments DMD Program Advances with Demo
Sarepta Investor and Media Contact: ecox@sareptatherapeutics.com Sarepta Therapeutics Announces Second Quarter 2012 Financial Results and Recent Corporate Developments DMD Program Advances with Demonstrated Clinical Benefit Marburg Program Shows Strong Efficacy with Delayed
Read more →SRPTAVI Media and Investor Contact: Erin Cox 425.354.5140 ecox@sareptatherapeutics.com AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to SRPT Effective Today Enacts rever
AVI Media and Investor Contact: ecox@sareptatherapeutics.com AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to SRPT Effective Today Enacts reverse stock split to strengthen financial base Reaffirms commitment to accelera
Read more →SRPTAVI Media and Investor Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance BOTHELL, WA
AVI Media and Investor Contact: AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance BOTHELL, WA, June 1, 2012 AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualificati
Read more →SRPTAVI Investor and Media Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI BioPharma Announces First Quarter 2012 Financial Results and Recent Corporate Developments Duchenne Muscular Dystrophy (DMD) and Infectious Diseas
AVI Investor and Media Contact: AVI BioPharma Announces First Quarter 2012 Financial Results and Recent Corporate Developments BOTHELL, WA, May 10, 2012 AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today reported financial results for the three m
Read more →SRPTAVI Media and Investor Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI Media Contact: David Schull 212.845.4271 David.schull@russopartners.com AVI BioPharma to Present Additional Data From the Phase IIb Study of Etepl
AVI Media and Investor Contact: David.schull@russopartners.com AVI BioPharma to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 AAN Annual Meeting Previously Reported Data Demonstrated Study Met Prima
Read more →SRPTAVI Investor and Media Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI Media Contact: David Schull 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Eteplirsen Meets Primary Endpoi
AVI Investor and Media Contact: 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of
Read more →SRPTAVI Investor and Media Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI Media Contact: David Schull 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Fourth Quarter and Full Year 20
AVI Investor and Media Contact: 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Recent Corporate Developments BOTHELL, WA, March 1, 2012 AVI BioPharma, Inc. (NASDAQ: AVII), a devel
Read more →SRPTAVI Media and Investor Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI Media Contact: David Schull 212.845.4271 David.schull@russopartners.com AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance B
AVI Media and Investor Contact: David.schull@russopartners.com AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualif
Read more →SRPTAVI Investor and Media Contact: Erin Cox 425.354.5140 ecox@avibio.com AVI Media Contact: David Schull Russo Partners 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Third Quarter 20
AVI Investor and Media Contact: 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Third Quarter 2011 Financial Results and Recent Corporate Developments Completed Enrollment With All Patients Receiving Ongoing Doses in Phase IIB Study of
Read more →SRPTAVI Investor and Media Contact: David Schull Russo Partners 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Second Quarter 2011 Financial Results and Recent Corporate Developments -
AVI Investor and Media Contact: 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Announces Second Quarter 2011 Financial Results and Recent Corporate Developments -Duchenne Muscular Dystrophy (DMD) Phase II Study of Eteplirsen Enrolling Begin Dos
Read more →SRPTAVI Media and Investor Contact: David A. Walsey Senior Director, Investor Relations & Corporate Communications 425.354.5140 Investorrelations@avibio.com AVI Media Contact: David Schull Russo Partners 858.717.2310 or 212.
AVI Media and Investor Contact: Senior Director, Investor Relations & Corporate Communications Investorrelations@avibio.com 858.717.2310 or 212.845.4271 David.Schull@russopartnersllc.com AVI BioPharma Provides Update on Initiation of Eteplirsen Phase 2 Clinical Trial BOTHE
Read more →SRPTAVI Media and Investor Contact: David A. Walsey Senior Director, Investor Relations & Corporate Communications 425.354.5140 Investorrelations@avibio.com AVI Media Contact: David Schull Russo Partners 212.845.4271 David.s
AVI Media and Investor Contact: Senior Director, Investor Relations & Corporate Communications Investorrelations@avibio.com David.schull@russopartnersllc.com AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer Experienced Clinical Leader in Rare Genetic Diseases from Ge
Read more →Competitive Position
How SRPT ranks across every disease it competes inCompetitive Position is a premium feature
See how SRPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial